- Home
- NVT vs RPRX Comparison
NVT vs RPRX Comparison
Compare NVT & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVT | RPRX |
|---|---|---|
| Founded | 1903 | 1996 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.7B | 22.0B |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NVT | RPRX |
|---|---|---|
| Price | $165.27 | $55.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $131.36 | $51.40 |
| AVG Volume (30 Days) | 2.0M | ★ 3.0M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | 0.61% | ★ 1.90% |
| EPS Growth | ★ 118.78 | N/A |
| EPS | ★ 0.87 | 0.67 |
| Revenue | ★ $3,893,100,000.00 | $2,378,193,000.00 |
| Revenue This Year | $19.44 | $38.63 |
| Revenue Next Year | $12.41 | $4.73 |
| P/E Ratio | $189.99 | ★ $81.43 |
| Revenue Growth | ★ 29.51 | 5.06 |
| 52 Week Low | $63.60 | $32.65 |
| 52 Week High | $175.00 | $54.74 |
Technical Indicators
Market Signals| Indicator | NVT | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 58.36 | 73.17 |
| Support Level | $152.20 | $35.35 |
| Resistance Level | $175.00 | N/A |
| Average True Range (ATR) | 6.10 | 1.02 |
| MACD | -1.62 | 0.13 |
| Stochastic Oscillator | 57.37 | 99.36 |
Price Performance
Historical ComparisonAbout NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.